<DOC>
	<DOCNO>NCT02638805</DOCNO>
	<brief_summary>A Phase 3b , open-label , randomize , multicenter , safety tolerability study ITCA 650 subject Type 2 diabetes take liraglutide metformin .</brief_summary>
	<brief_title>Study Safety Tolerability Switching ITCA 650 Patients With Type 2 Diabetes Receiving Liraglutide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosis type 2 diabetes ≥ 3 month . Stable regimen diet exercise combination stable treatment liraglutide ≥1.2 mg/day metformin ≥1000 mg/day . HbA1c ≤9.5 % . Stable body weight ≥ 3 month . Body mass index ( BMI ) ≥25 ≤45 kg per meter square . Calcitonin &lt; 50 ng/L ( 50 pg/mL ) Screening Visit . History type 1 diabetes . Recent use antidiabetic medication liraglutide metformin . History significant/severe nausea and/or vomit due liraglutide . Significant symptomatic hyperglycemia . History evidence , within last 6 month prior Screening Visit , myocardial infarction , coronary revascularization ( coronary artery bypass graft percutaneous coronary intervention ) , unstable angina , cerebrovascular accident stroke . History evidence acute chronic pancreatitis . History liver disease . History medullary thyroid cancer family personal history multiple endocrine neoplasia type 2 . Poor thyroid , liver , renal function . Serum creatinine level &gt; 1.5mg/dL ( 132 μmol/L ) male patient , &gt; 1.4 mg/dL ( 123 μmol/L ) female patient . Weight loss surgery require weight loss medication . History malignancy ( include basal squamous cell carcinoma skin past 5 year ) . History active alcohol substance abuse . Treatment medication affect GI motility . History hypersensitivity exenatide liraglutide . Women pregnant , lactating , plan become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>